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Abstract 
Human papillomaviruses (HPVs) are the most common sexually transmitted infections. 
Persistent infection with HPV can lead to anogenital cancers including head and neck 
cancers. Three prophylactic vaccines have been approved to prevent against some types 
of HPV infection. However, the vaccines are HPV-type specific and protect mostly 
against the HPV types included in the vaccines. To offer broader protection against more 
HPV types, studies in the field are developing candidate vaccines targeting a conserved 
minor capsid protein, L2. Nevertheless, reagents for developing and assessing L2 
vaccines are limited. For example, antibodies to assess the antigenicity of some L2 
epitopes are not available commercially and multivalent platforms to develop and purify 
clinical grade L2 antigens are limited. In this study, I developed and characterized the 
immunogenicity of a recombinant Histidine-tagged HPV16 L2 (amino acid 1-130) 
antigen. In addition to this, I explored the development of a multivalent display platform, 
a recombinant MS2-bacteriophage coat protein, with a C-terminal Arginine-tag for 
downstream purification using cation exchange chromatography. All Recombinant 
proteins (Histidine-tagged L2 and MS2-Arg tagged) were successfully expressed in 
bacteria. However, only Histidine-tagged L2 proteins were successfully purified in large 
quantity to homogeneity. Mice immunized with the Histidine-tagged L2 protein elicited 
anti-L2 IgG antibody titers greater than 103. The anti-L2 antibodies generated in this 
study will be valuable to researchers, in the field, developing L2 vaccines.  
 
 
 1 
Overview 
Affinity-tagged proteins are recombinant proteins fused/linked to a polypeptide sequence 
(an affinity tag) with potentials to bind to a specific chemical or a biological ligand [1, 2]. 
A number of affinity tags can be genetically fused to a protein and each tag binds to a 
specific ligand. For example, Histidine tag binds to metal ion ligand (Ni2+-NTA, Co2+-
CMA), Arginine tag binds to cation exchanger (SP sepharose and CM saphadex beads), 
C-myc tag binds to Mab 9E10 antibody, and  FLAG tag binds to M1 monoclonal 
antibody [1, 3] . There are so many advantages of tagging a protein. i) An affinity tag 
enables the fused protein of interest to be purified from a mixture of contaminating 
proteins. For example, histidine, glutathione, and arginine affinity tags facilitate protein 
purifications [1, 2, 4]; ii) Adding an affinity tag to a protein enables the protein of interest 
to be identified using antibodies that are specific to the tag. For example, c-myc tag on a 
protein facilitates protein detection using c-myc-specific antibodies; iii) An affinity tag 
enhances protein solubility. For example, the addition of a glutathione tag to a protein 
enhances the solubility of the protein.  
Affinity tags have been used in the past to purify large quantities of affinity-tagged 
proteins (from contaminating proteins) for proteomics [1], bio-therapeutics, vaccine 
studies, etc. [2]. In this study, we explored the ability to express and purify two 
recombinant proteins [human papillomavirus (HPV)16 L2 protein and bacteriophage 
MS2 coat protein] from bacterial lysate using histidine affinity tag (Part I) and arginine 
affinity tag (Part II), respectively. These two tags were chosen because they are very 
small (6 amino acids) and they are less likely to interfere with the immunogenicity of our 
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proteins of interest [1]. Purified HPV16 L2 and MS2 proteins were explored as reagents 
for vaccine-related studies.  
Part I 
Development and characterization of the immunogenicity of a 
recombinant Histidine-tagged HPV16 L2 protein (amino acid 1-130) 
 
1. Introduction 
1.1 Human papillomaviruses L2 (aa 1-130) 
Human papillomaviruses (HPVs) are the most common sexually transmitted infections 
[5, 6]. HPVs are non-enveloped viruses with a double-strand circular DNA genome (8 
KB). The genome is surrounded by an icosahedral capsid, which is composed of two 
capsid proteins, the major capsid protein (L1) and the minor capsid protein (L2) [7, 8].  
HPVs cause about 5% of cancer cases globally [8-10]. More than 200 types of HPVs 
have been identified [11]. They can be classified into two genotypes based on the type of 
lesions that they cause: High-risk HPV (HR-HPV) and Low-risk HPV (LR-HPV). HR-
HPVs cause cancer such as anal, vulvar, vaginal, cervical, penile, and head & neck 
cancers [7, 9]. More than 18 HR-HPVs (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68, and 73) [11] have been identified. Globally, HPV16  and HPV 18 cause 50% and 
20% of cervical cancer, respectively   [5, 7]. The Low-risk HPVs (HPV6, 11, 42) cause 
warts for example, genital warts. 
Worldwide, more than 500,000 people per year are diagnosed with cervical cancer from 
HPV infection [12]. HPV-associated cancers in addition to HPV-associated genital warts 
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treatments are very expensive, and may be as high as more than 4 billion dollars annually 
[13]. This puts a lot of financial pressure on the healthcare system [5, 8, 13]. Fortunately, 
three vaccines have been developed within the last decade to protect against HPV 
infections [11]. Cervarix, Gardasil-4, and Gardasil-9 vaccines consist of virus-like 
particles (VLPs) derived from the L1. Two of these vaccines (Cervarix and Gardasil-4) 
provide protection mostly against HPV16 and 18. Gardasil can also protect against HPV6 
and 11. Gardasil-9 is composed of 9 VLPs and protects against HR-HPV types (HPV16, 
18, 31, 33, 45, 52, 58) and LR-HPVs (HPV6 and 11)[11].  Thus, Gardasil-9 can protect 
against the HPV types that cause 90% of cervical cancer. 
 Although the available vaccines induce high immune responses, they do not protect 
against other HPV types not included in the vaccines; the vaccines are type-specific [11].  
Given the fact that the vaccines do not protect against all HPV types that cause cancer, 
medical practitioners still recommend that women who have been vaccinated with the 
vaccines should continue screening for cervical cancer to make sure that they are not 
infected with HPV types not included in the vaccines. As an alternative to L1 vaccines, 
other studies have focused on developing HPV vaccines targeting a conserved protein, 
the minor capsid, on the capsid. The minor capsid protein, L2, is conserved among HPV 
types as shown in figure1. Several studies have shown that L2 is able to elicit cross-
neutralizing antibodies against most HPV types [9, 14, 15]. For example, immunization 
with L2 synthetic peptides (derived from HPV16) corresponding to amino acids (aa) 17-
36, 34–52, 49–71, 56-75, 65-85, 108-120 elicited cross-neutralized against heterologous 
HPV pseudoviruses 18, 31, 45, 58 [16-18]. However, the cross-neutralizing antibody 
titers against these HPV types were less than 200 compared to neutralization of 
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homologous HPV pseudovirus 16 (with neutralization titers ranging from 400-3200) [16]. 
In order to enhance the immunogenicity of some of these epitopes, researchers have 
immunized mice with concatemers of these peptides [19, 20], immunized with L2 peptide 
conjugated to thioredoxin [21, 22], or immunized mice with virus-like particles (VLPs) 
displaying the L2 peptides on the surface of the VLPs [6, 23, 24, 25, 26]. Most of these 
strategies enhanced the immunogenicity of the L2 peptides especially those displayed on 
VLPs. VLPs displaying L2 peptides elicited broad protection against diverse HPV types 
after two immunizations with small doses (only 5 µg per immunization) of VLPs [14, 27, 
28, 29]. Thus, VLPs are excellent platforms that can be used to enhance the 
immunogenicity of less immunogenic peptides and they can be used at lower doses with 
1-2 immunizations. Despite these advantages, there are some challenges in developing 
recombinant VLPs displaying HPV L2 peptides. One challenge is purifying the 
recombinant VLPs from other contaminating bacteria proteins; another challenge is to 
confirm that L2 peptides are displayed on the surface of the VLPs prior to immunization. 
The display of L2 peptides on the VLPs is a pre-requisite for a good immune response. 
Our lab including others in the field have inserted L2 epitopes on the surfaces of VLPs 
derived from different viruses.  . For example, our lab has inserted epitope 108-122 
(representing amino acid 108-122) on the coat protein of MS2 bacteriophage. However, 
we do not know whether this epitope is displayed on the surface of MS2 VLPs following 
the assembly of recombinant MS2-L2 coat protein into VLPs. This could have easily 
been demonstrated with enzyme-linked immunosorbent assay (ELISA) using anti-L2 sera 
(especially against epitope 108-122); however, antibodies targeting this epitope and 
others are not available commercially. The objectives of this thesis were:  
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i) develop an L2 protein (amino acid 1-130) from HPV16 and to generate polyclonal 
antibodies against this protein. Availability of antibodies targeting L2 epitopes will 
enhance vaccine research that targets L2 protein. To enhance the purification of 16L2   aa 
1-130, we decided to generate a recombinant L2 protein fused to a Histidine (His) affinity 
tag. 
ii) Assess the possibility of displaying an Arginine (Arg) affinity tag on the surface of 
MS2 VLPs that could be used to purify recombinant MS2 VLPs from other 
contaminating bacteria proteins. An affinity tag on MS2 VLPs will enable the 
purification of the recombinant VLPs to homogeneity.  
1.2 Affinity tags 
Affinity tags are a peptides or proteins that bind with high affinity to their respective 
matrix such as chemicals or even other proteins. The commonly used tags are Histidine 
(His) tag, Arginine (Arg) tag, Maltose-binding protein, C-myc tag, glutathione S-
transferase tag, FLAG tag, etc. [1].  Each tag has a specific matrix for binding. For 
example: His-tag binds to Ni-nitrilotriacetic acid (NTA) matrix or other metal ion,  Arg-
tag binds to SP sepharose and CM saphadex beads, Maltose binding protein binds with 
cross-linked amylose matrix, C-myc binds to Mab 9E10 antibody,  glutathione S-
transferase tag binds with immobilized glutathione,  and FLAG tag bind to monoclonal 
antibody matrix [1, 3, 30]. 
Following binding of tags to their cognate matrix, unbound protein can be washed away 
and bound tagged-protein eluted from the matrix, yielding a very pure protein/peptide. 
These tags have been exploited to enhance the purification of proteins by fusing the tags 
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to proteins of interest [1]. To enhance the purification of L2 protein from other 
contaminating bacteria proteins, we chose Histidine (His, contains 6 Histidine residues).  
This tag was chosen because it is very small, may not interfere with protein folding and 
does not interfere with the immunogenicity of the recombinant protein [1]. 
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Figure 1. L2 (aa 1-130) sequence alignment of different types of High and low risk of HPVs. Alignment was done using Jalview 
software. Conserved residues are shown in yellow bars below 
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2. Materials and Methods  
2.1 Cloning and screening for the expression of a recombinant His-
tagged HPV16 L2 protein (aa 1-130).  
 An HPV16L2 DNA sequence (representing amino acid, aa 1-130), linked directly at the 
N-terminus by six Histidine residues (His-tag) was codon-optimized for bacterial 
expression and was synthesized by Epoch Life Science. To enable cloning of the DNA to 
a bacterial expression plasmid, two restriction sites (an Nco1 restriction site with a start 
codon at N-terminus and a BamH1-HF restriction site at C-terminus) were added to the 
DNA sequence. Two nucleotides were added between the Nco1 site and His-tag to enable 
in-frame cloning. The synthesized DNA fragment (430 base pair, bp) in figure 2 was used 
as a template for polymerase chain reaction (PCR).  
 
                             
 
 
 
 
 
 
 
 
 
 
 
The PCR reactions consisted of a mixture 10µM of forward primer (Table 1), 10µM 
reverse primer (Table 1), 1X OneTaq Hot Start master mix, 10 ng of DNA template (i.e. 
AGCGCCATGGCTCATCATCACCACCATCACCGTCACAAACGTTCTGCTA
AGCGCACTAAACGTGCATCCGCAACCCAGCTGTACAAGACCTGTAAAC
AGGCTGGCACCTGCCCACCAGACATCATTCCGAAAGTTGAAGGTAAGA
CCATCGCTGATCAGATCCTGCAGTATGGCAGCATGGGTGTGTTCTTCGG
TGGCCTGGGTATTGGTACTGGCTCTGGTACTGGTGGTCGTACCGGCTAC
ATCCCACTGGGCACTCGTCCACCGACTGCGACTGACACCCTGGCACCG
GTACGTCCACCACTGACCGTTGATCCAGTTGGTCCGAGCGATCCGTCTA
TTGTATCTCTGGTGGAAGAAACTTCTTTCATCGATGCAGGTGCTCCGAC
CTCTGTGCCATCTATTCCACCAGATGTGTAAGGATCCTTCT 
 Figure 2. Synthesized DNA sequence of His-tagged HPV16 L2 (aa 1-130). The 
nucleotides with green background are Nco1 (left) and BamH1-HF (right) restriction 
sites. The nucleotides in red (left) indicates the start codon and the nucleotides in red 
(right ) indicates the stop codon. Six histidine residues (His-tagged; highlighted in yellow 
background) are linked to N-terminus of HPV16 L2 (sequence in white background 
between his-tag and stop codon)  
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the synthesized His-tagged L2 DNA), and DI water. Negative PCR control was set up as 
above except that template DNA was not used. The PCR conditions used are shown in 
Table 2. 
Table 1: Sequences of primers used for PCR amplification of His-tagged L2 DNA 
Primers DNA sequences Restriction 
sites* 
Forward 
primer 
(CONS. 
L2 S& 
(16E5-
E7)  
5’ AGCGCCATGGCTCATCATCACCAC 3’ Nco1 
Reverse 
primer 
L2(1-
130)R 
5’ AGAAGGATCCTTACACATCTGGTGGAATAGATGGTG 
3’ 
BamH1-
HF 
 
*Forward primer sequence consisted of Nco1 restriction site highlighted in green background. It 
also includes the start codon highlighted in red text. Reverse primer sequence contained stop 
codon (red text) followed by BamH1-HF restriction site (highlighted in green background). 
Table 2 : Thermocycling condition for His-tagged HPV16 L2 DNA 
step Temperature Time 
Initial denaturation 94 ºC 2 minutes 
Denaturation 94 ºC 30 seconds 
Annealing 58 ºC 30 seconds 
Extension 68 ºC 30 seconds 
Final Extension 70 ºC 5 minute 
Hold 4 ºC ∞ 
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After PCR, the samples including a 1Kb DNA ladder were run on a 1% agarose gel 
stained with 0.5 ng/µl ethidium bromide and a photo of the gel was taken following a 
brief observation on a UV Transilluminator. 
2.2 Purification of DNA from the gel and digestion  
The DNA band was cut from agarose gel and DNA was extracted from the gel using 
Qiagen Gel Extraction kit protocol. For cloning to a pDSP62 plasmid, the extracted DNA 
and the plasmid were separately digested with restriction enzymes as followings: 
Purified His-tagged-L2 DNA  
-30 µl of amplified DNA 
-4.0 µl of 10X cut smart buffer 
-0.75 µl of NcoI Restriction enzyme  
-0.75 µl of BamHI-HF Restriction enzyme  
-4.5 µl DI water  
Reaction total volume: 40 µl 
Plasmid pDSP62  
-1.0 µl of each restriction enzyme (NcoI and BamHI-HF)  
-5µ l of 10X cut smart buffer  
-24 µl (3000ng) pDSP62 plasmid 
-9 µl DI water 
Reaction total volume: 40 µl 
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All reaction mixtures were incubated overnight at 37ºC after which they were separated 
on a 1% agarose gel. A larger band 3,819 bp from the digested pDSP62 plasmid and a 
band 409 bp from the amplified His-tagged-L2 DNA were cut from the gel and the DNAs 
were extracted from gel slices using Qiagen Gel Extraction kit protocol. 
2.3 Ligation of DNA to plasmid vector (pDSP62) 
The digested His-tagged-L2 DNA was ligated into digested pDSP62 plasmid as follows: 
-6 µl of digested His-tagged-L2 DNA 
-1.5 µl of digested pDSP62 plasmid 
-1 µl of 10X ligase buffer 
-0.5 µl of T4 Ligase enzyme 
-1 µl of DI water 
 Total volume of reaction was 10µl. The ligation reactions were incubated overnight at 
room temperature or over the weekend at 4ºC.  
2.4 Transformation of ligated plasmid to C41 E. coli cells 
The ligated DNA was transformed into C41 E. coli bacteria by heat shock as follows. 
Ligated plasmid DNA was mixed with C41 E. coli competent cells and was incubated in 
ice for 30 minutes.  After that, the mixture was transferred to a 42ºC water bath for 90 
seconds and then back into ice for 5 minutes. Eight hundred µl of Luria Bertani (LB) 
media without antibiotic was added to the mixture and the mixture was shook for 1 hour 
at 37ºC. The transformation mixture was then centrifuged for 4 minutes at 3000 rpm and 
400µl of the supernatant was discarded and the pellet resuspended in the remaining 
supernatant. One hundred µl of resuspended solution was spread on agar plates 
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(contained 50 ng/µl kanamycin antibiotic). The kanamycin plates were incubated 
overnight at 37ºC. 
2.5 Screening colonies for protein expression  
Colonies were picked up from the agar plates and put in separate tubes with 600µl of LB 
media containing 50 ng/µl kanamycin antibiotic. The culture tubes were then incubated at 
37ºC for 3 hours. When the solution became cloudy, 250µl of cultures were transferred to 
new tubes and induced with 0.5 µM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The 
IPTG-induced tubes and uninduced tube were shook for additional 3 hours at 37ºC. After 
3 hours, 250µl from one of the uninduced tube was taken as an uninduced negative 
control and the tube together with culture from induced tubes were centrifuged at 10,000 
rpm for 5 minutes. The supernatants were discard and the pellets were resuspended in 
70µl of 8M urea to lyse the bacteria. The samples were sonicated to further lyse the cells. 
From each sonicated sample, 15µl was transfer into small tubes and mixed with 5µl of 
5X protein loading dye. This was then heated for 5 minutes at 95ºC to denature the 
samples. Ten µl of heated samples including the uninduced control were loaded on a 12% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel to check for 
protein expression and the size of the expressed protein. In addition to this, 2µl of protein 
ladder was loaded to estimate the protein size. The gel was run for 60 minutes at 160 
voltage after which the gel was washed and stained with Coomassie Blue dye. The gel 
was then washed and microwaved with paper towels to destain it.  
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2.6 Plasmid preparation and sequencing of constructs  
After checking for His-tagged-L2 protein expression, the construct with highest protein 
expression was selected for plasmid extraction and sequencing to confirm the cloned 
sequence. Plasmid extraction was done using a QlAprep Spin Miniprep Kit and the 
concentration of the DNA (135 ng/µl) was determined using Nanodrop. A restriction 
digest was set up using DNA from plasmid prep to confirm that the DNA size released 
from the plasmid was identical in size to the cloned His-tagged-L2 DNA.  
The restriction digest reaction was set up as follows: 
-3 µl extracted plasmid DNA  
-1.0 µl of 10X cut smart buffer,  
-0.25 µl of NcoI Restriction enzyme  
-0.25 µl of BamHI-HF Restriction enzyme  
-5.5 µl DI water  
Reaction total volume: 10 µl  
The reaction mixtures were incubate at 37°C for 4 hours after which the digested samples 
were run on a 1% agarose gel. Also, DNA ladder was run to indicate the DNA size. To 
confirm the His-tagged-L2 (1-130) DNA sequence, a sample of DNA plasmid was send 
to Arizona State University for sequencing using T7 promoter primer. 
2.7 Purification of His-tagged L2 protein 
After ensuring the accuracy of DNA sequence, a large-scale culture from sequenced 
construct was started for the expression and purification of recombinant protein. First, 50 
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µl of C41 E.coli bacteria expressing the cloned His-tagged L2 protein was used to 
inoculate 2 ml of LB media in the presence of 50 ng/µl kanamycin and shook at 37°C 
overnight. Next day, 1ml from the overnight culture was used to inoculate 50 ml of LB 
media (with 50 ng/µl Kanamycin antibiotic). The cultures were then shook for 4 hours 
until the cell density reached 600 Optical Density (OD) and became cloudy. Because the 
His-tagged L2 protein was expressed from a T7 promoter, the culture was induced with 
0.5 mM IPTG and shook for additional 3 hours at 37ºC. The induced culture was 
centrifuged for 20 minutes at 10,000rpm to pellet the cells. The pellet was resuspended in 
10 ml of lysis/equilibration buffer (8M Urea, 20mM Na2HP2O4, 300mM Na2Cl, and 
10mM Imidazole; pH 7.5) and incubated in ice for 20 minutes. The cells were then 
sonicated for 5 minutes to lyse them. Fifty µl of lysate from sonicated cells were saved 
for SDS PAGE to confirm L2 protein expression in total protein fraction. After that, the 
culture was centrifuged for 10 minutes at 10,000 rpm.  
Because the L2 protein had His-tagged inserted in the N-terminal of L2, a Thermo Fisher 
protocol (Nickel beads; Ni-NTA) was adapted to purify the L2 protein. First, 4 mL of Ni-
NTA beads was placed in a bottom-capped purification column. The Ni-beads were 
allowed to settle down in the column by gravity and the column was then uncapped to 
drain the supernatant. The Ni-beads were equilibrated in 3ml of lysis/equilibration buffer 
twice and each time, Ni-beads were, allowed to settle down by gravity. The bottom of the 
column was then uncapped to drain the equilibration buffer. To bind L2 protein with Ni-
beads, 10ml of the L2 protein (from above) was added to the column and rocked for 45 
minutes at room temperature using a rotator. After that, the Ni-beads were allowed to 
settle by gravity and the column was uncapped and flow-through solution was collected 
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into a tube and labeled as unbound. The column was washed three times each with 3ml of 
washing buffer (8M Urea, 20mM Na2HP2O4, 300mM Na2Cl, and 20mM Imidazole; pH 
6). The column was incubated at room temperature for two minutes in-between washes 
and all the washes were collected in newly labeled tubes, “washed”. Following the last 
wash, 4ml of Elution buffer (8M Urea, 20mM Na2HP2O4, 250mM Na2Cl, and 250mM 
Imidazole; pH 8) was added to the column and the bottom of the column uncapped and 
1ml fractions of eluted protein were collected in several tubes. To assess which fraction 
had the protein of interest and its purity, 10µl of all eluted fractions, 10µl of washed 
supernatant, 10µl of unbound proteins, and 10µl of lysate that was collected before the 
purification began were each mixed with SDS PAGE loading dye and each mixture 
heated for 5 minutes at 95°C. The mixtures were then run on an SDS PAGE gel and 
protein fractions with the highest purity were then combined. To remove urea from the 
purified protein (a process which can help refold the protein), the protein was put into 
SnakeSkin Dialysis Tubing [10,000 Molecular Weight Cut Off, MWCO] and the tubing 
placed in 800mL of 1X Phosphate-Buffered Saline (PBS) buffer. The tubing was 
incubated and stirred overnight at 4ºC after which the PBS buffer was changed and the 
protein dialyzed for 8 additional hours at 4ºC. To estimate the concentration of purified 
His-tagged L2 protein, 5µl and 10µl of the dialyzed protein together with known 
concentrations (10µg, 5µg, 2.5µg, and 1µg) of hen egg lysozyme (HEL) were loaded in 
separate walls. The concentration of His-tagged L2 protein was then estimated by 
comparing the intensity of the His-tagged L2 protein band to those of lysozymes. 
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2.8 Mice immunization  
To induce antibodies against the purified L2 protein, 4 Balb/c mice were immunized 
intramuscularly (3 times at two weeks interval) with 10µg (per immunization) of His-
tagged L2 protein plus alum adjuvant. Another group of mice, control, was not 
immunized. Sera were collected from the mice two weeks after the last immunization to 
check for antibodies (described below) against HPV16 L2. 
2.9 Enzyme-Linked Immunosobent Assay (ELISA)  
In order to determine antibody titers in sera from mice immunized with the His-tagged 
16L2 protein, an ELISA was done as follows. An ELISA plate was coated with 500 ng of 
purified 16L2 (aa 1-130) and the plate was incubated at 4ºC overnight. The plate was 
then blocked for 2 hours at room temperature with blocking buffer (0.5% nonfat dry milk 
in PBS buffer). The blocking buffer was then discard and 4-fold serial dilutions of sera 
from His-tagged 16L2 (aa 1-130) immunized mice or from unimmunized mice were then 
added to the plate. As a positive control, sera from HPV16 L2 (aa 1-88) was also diluted 
serially and added to wells in the ELISA plate. The plate was then incubated for 2 
additional hours (rocking) at the same temperature. After two hours, the wells in the 
ELISA plate were washed four times with PBS buffer.  Horseradish peroxidase-
conjugated goat anti-mouse IgG (secondary antibody) at 1:5000 dilution was added and 
the plate incubated for 1 hour (rocking) at room temperature. After that, the wells were 
washed five times with PBS. Fifty µl of 3,3’,5,5’-Tetramethylbenzidine (TMB) solution 
was added to each well to develop ELISA plate. After 13 minutes, the solution changed 
to blue color, and to stop the reaction, 50µl of 1% of HCl was added to each well. The 
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OD value of the solution was determined at 450nm using a plate reader. The titers of 
antibodies were determined as the reciprocal of the highest sera dilution with an OD450 
greater than 2-fold that of control sera at the same dilution. The values were graphed 
using GraphPad 5.0 Prism software.  
2.10 Western Blotting 
Western blotting was done to confirm the ELISA results as well as to confirm the size of 
the purified His-tagged L2 protein. The assay was done as follows. Two different 
concentrations (500ng and 1000ng) of His-tagged L2 protein were loaded on an SDS 
PAGE. Five hundred ng of MS2 also was loaded as a negative control and the gel was 
run as described above. The gel was then transferred to a Polyvinylidene difluoride 
(PVDF) membrane. The gel and the PVDF membrane were sandwiched between 3mm 
Whatman filter papers soaked in 1X transfer buffer (760 ml of Ultra-pure water, 40ml of 
the mixture: Tris base 18.2 g, Glycine 90.0g, and 500ml of ultra-pure water, and 200ml of 
methanol). The sandwich (filter paper, gel, membrane, filter papers) was put in an XCell 
II Blot Module and the module placed in an SDS PAGE electrophoresis tank. The XCell 
II Blot (middle part of tank) was filled to the top with transfer buffer while outer part of 
the tank was filled with 650ml of DI water. The protein was then transferred from the gel 
to the membrane at 30 voltage for one hour. After transferring the L2 proteins to the 
membrane, the membrane was blocked (rocking overnight at 4ºC) using blocking buffer 
(5% nonfat dry milk in 1X of Tris buffered Saline with 0.05% Tween-20; TTBS). The 
membrane was then washed with TTBS buffer and 1:5000 dilution of his-tagged L2 (aa 
1-130) sera diluted in blocking buffer was added to the membrane. The 
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membrane/solution were rocked for two hours at room temperature. The membrane was 
rinsed four times (each with five minutes incubation) with 1X TTBS. After that, 1:5000 
dilution of secondary antibodies (HRP conjugated goat anti-mouse IgG) diluted in 
blocking buffer was added to the membrane. The membrane was rocked with diluted 
secondary antibodies for one hour at room temperature. After that, the membrane was 
washed three times (5 minutes each) and the membrane was developed using a mixture 
that consisted of equal volumes of SuperSignal West Pico Lumino/Enhance solution and 
SuperSignal West Pico Stable Peroxide solution. The membrane was incubated for five 
minutes after adding the mixture. The membrane was then wrapped in saran wrap and 
scanned using Luminescent Image Analyzer (LAS-4000) mini equipment to detect 
protein bands that reacted with the L2 antibodies. 
3. Results  
Recombinant His-tagged HPV16 L2 (aa 1-130) was successfully amplified by PCR. As 
shown in figure 3, a 430 bp DNA fragment corresponding to the L2 protein (390 bp), 6 
his-tag (18 bp) plus restriction site sequences including flanking nucleotides was 
obtained. There was no amplification of negative control sample thus suggesting that the 
PCR was not contaminated.  
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Figure 3. Electrophoretic mobility of amplified DNA (His-tagged plus HPV16L2 aa 1-
130) in 1% agarose gel stained with ethidium bromide. Number 1 is a PCR negative 
control, number 2 and 3 are recombinant His-tagged plus HPV16L2 (aa 1-130) DNA, 
and number 4 was 1 Kb DNA ladder 
To clone the amplified His-tagged HPV16 L2 DNA to pDSP62 plasmid, amplified DNA 
and plasmid were separately digested with Nco1 and BamH1-HF restriction enzymes. As 
shown in figure 4, the digested plasmid gave rise to two bands ( 800bp and 3,800 bp).  
Ligation of the circled bands from the gel and transformation of C41 cell gave rise to 
many bacteria colonies on kanamycin agar plate (data not shown). Plasmid pDSP62 is 
kanamycin resistant and the growth of bacterial colonies on the agar plate suggested the 
C41 cells were transformed with the ligated plasmid. 
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Figure 4. Agarose gel stained with ethidium bromide showed the size of digested 
amplified DNA and plasmid using restriction enzymes (NcoI-Bam-H1-HF), Number 1 
and 2 are digested His-tagged 16HPV L2 (aa1-130)DNA ,  Number 3 and 4 , digested 
plasmid pDSP62; the circled band were purified and ligated. Number 5 was 1Kb DNA 
ladder 
 
Bacterial colonies that were screen for protein expression showed that His-tagged L2 (aa 
1-130) was cloned into the pDSP62 vector and the protein was expressed. As shown in 
the SDS PAGE in figure 5, a band of ~15.07KD was observed in samples that were 
induced with IPTG but not on uninduced sample.  
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Figure 5. SDS-PAGE stained with Coomassie blue showing protein expression in 
different colonies. Number1 is uninduced recombinant His-tagged L2 (aa 1-130) protein. 
Number 2-8 represent bacteria from colonies induced with IPTG .Number 9 is protein 
ladder. Circle indicates His-tag L2 (aa 1-130) protein expression 
 
To confirm the DNA size and the sequence of the cloned His-tagged L2 (aa 1-130) DNA, 
plasmid preps and restriction digests, using the same cloning enzymes, were set up. As 
shown in figure 6, a fragment of ~409 bp was released following restriction digest 
confirming the cloning of His-tagged L2 (aa 1-130). Sequencing confirmed the cloned 
DNA sequence figure 7. 
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Figure 6.  Plasmid prep. Agarose gel stained with ethidium bromide showed the size of 
digested amplified DNA and plasmid using restriction enzymes( NcoI and Bam-HI-HF). 
Lower band in lane 1 showed inserted His-tagged 16HPV L2 (aa1-130) DNA, whereas 
the upper band in the same lane represented plasmid pDSP62; Lane 2 was 1Kb DNA 
ladder 
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Figure 7. Sequence alignment of His-tag 16HPV L2 (aa 1-130) DNA (Query sequence; 
cloned sequence) showed 100% identity with sequence that was synthesized (sbjct, which 
represents subject sequence). Sequence Alignment was done using nucleotide BLASTN 
 
To purify the expressed recombinant His-tagged L2 (aa 1-130) protein, Ni2+ beads were 
used. Six His-tagged was attached to L2 to facilitate protein purification using Ni2+ 
beads. As shown in figure 8, when the total protein (Number 2) was added to Ni2+ beads 
in a chromatography column, non-His-tagged bacterial proteins did not bind to the beads 
(Number 3). Similarly, when the column was washed, non-His-tagged residual bacterial 
proteins flew out of the column (Number 4) leaving His-tagged L2 (aa 1-130) protein 
attached to the Ni2+ beads. When the protein was eluted with elution buffer (has high 
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concentration of imidazole), only the his-tagged protein was eluted from the column in 
fractions 2 and 3 (Number 6 and 7 on the gel).   
 
 
Figure 8. Purification of recombinant protein His-tagged L2 (aa 1-130) protein. The 
recombinant protein was purified in a chromatograph column using Ni-NTA beads. 
Number 1 is marker, number 2 is total protein before purification, number 3 unbound 
protein (flow through) after adding total protein to column, number 4 is flow through of 
column wash, and numbers 5-8 are fractions 1,2,3,4, respectively of eluted protein 
 
The concentration of the purified His-tagged L2 (aa 1-130) protein was determined to be 
250ng/µl. Figure 9 shows band intensities of protein in comparison to known 
concentrations of hen egg lysozyme.  
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Figure 9. Estimation of His-tagged L2 (aa 1-130) protein on an SDS PAGE gel based on 
known concentrations of hen egg lysozyme (HEL). Number 1 is 10 µg, number 2 is 5µg, 
number 3 is 2.5µg, and number 4 is 1µg of HEL. Numbers 5 and 6 are 5ul and 10ul, 
respectively, of purified his-tagged L2 (aa 1-130) protein. The circled band had similar 
intensity with 2.5µg of HEL 
 
To assess the immunogenicity of the purified His-tagged L2 (aa 1-130) protein, mice 
were immunized with the protein. Sera were collected after the last immunization and 
IgG antibodies in sera were determined by ELISA. As shown in figure 10, mice 
immunized with the purified His-tagged L2 (aa 1-130) had antibody titers (greater than 
103) similar to IgG titers in our positive control sera (from mice previously immunized 
with 16L2, aa 1-88). However, IgG titer from unimmunized mice was very low (102). 
The ELISA results were confirmed using Western Blotting. As shown in Figure 11, a 
band of approximately 15.07KD reacted with serum from mice immunized with His-
tagged L2 (aa 1-130); serum reacted with His-tagged L2 (aa 1-130) even at a lower 
concentration (500ng) of the protein. , As expected, the serum did not react with negative 
control MS2 coat protein confirming that the serum is specific to HPV L2. 
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Figure 10. IgG antibody titers in immunized or unimmunized mice. Four Balb/c mice (per 
group) were immunized (3 times) intramuscularly with 10ug (per immunization) of 
recombinant L2 protein plus alum adjuvant. Two weeks after the last immunization, sera 
were collected and antibody titers were determined by end-point dilution ELISA. Each 
datum represents serum from an individual mouse 
 
 
Figure 11. Reactivity of His-tagged L2 (aa 1-130) sera in a Western blot. MS2 coat 
protein (negative control), His-tagged L2 (aa 1-130) proteins were probed with 1:5000 
dilution of serum from mice immunized with His-tagged L2 (aa 1-130) protein. Arrow 
indicates His-tagged L2 (aa 1-130) proteins 
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4. Discussion 
In this study, we successfully cloned and purified His-tagged L2 (aa 1-130) protein from 
bacterial lysate using Ni-NTA beads.  Six Histidine residues attached to the L2 protein 
enhanced the purification of L2 protein to homogeneity from bacterial cells. Mice 
immunized with the His-tagged L2 (aa 1-130) protein elicited antibodies (with titers more 
than 103) against the L2 protein. As mentioned earlier, one of the challenges in 
developing candidate L2 HPV vaccines is to demonstrate that L2 peptides/epitopes are 
displayed on the surface of a multivalent platform (such as VLPs), which is a prerequisite 
for a robust immune response. The anti-HPV16 L2 (aa 1-130) antibodies generated in this 
study will be a valuable reagent for researchers in the field developing HPV vaccines 
targeting the minor capsid protein, L2. The anti-L2 sera could be used to confirm (by 
ELISA or Western blot) the display of L2 peptides on the surface of a multivalent 
platform such as VLPs. 
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Part II 
Insertion of an Arg affinity tag on MS2 VLPs to enhance purification of 
recombinant MS2 VLPs 
1. Introduction 
As mentioned earlier, virus-like particles (VLPs) are excellent platforms for enhancing 
the immunogenicity of peptide antigens [31]. VLPs can be derived by overexpressing the 
coat (capsid) protein of a virus using a plasmid. Following overexpression, the coat 
protein spontaneously assembles to form VLPs. The VLPs look like the virus from which 
the coat protein was derived from; i.e. their ability to display epitopes to the immune 
system in a highly multivalent format. This property makes them very immunogenic [14, 
31, 32]. VLPs do not contain the whole viral genome. Thus, they are not infectious and 
are safe vaccine platforms[33]. Although VLPs can be derived from any virus, our lab is 
interested in using VLPs from viruses that infect bacteria (bacteriophages: MS2, Qβ, and 
PP7) as display platforms [14, 31]. They can easily be expressed and purified by gel 
filtration in large quantities (milligrams) from bacteria. Although gel filtration (using 
sepharose CL-4B beads to separate protein based on size) removes most contaminating 
bacterial proteins, the purity of the recombinant VLPs could be improved. In this study, 
we assessed whether an Arginine (Arg) tag inserted on the C- terminus of MS2 single-
chain dimer could be used to purify recombinant MS2 VLPs (by cation exchange 
chromatography[1]). We chose an Arg tag (tag contains 6 arginine residues) because it is 
very small, it may not interfere with the assembly of MS2 coat proteins into VLPs or 
interfere with the immunogenicity of the recombinant protein. Six or five amino acids are 
commonly used in the construction of Arg tag and the tag can be inserted in the N- or C-
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terminus of a protein of interest [1, 3].  The Arg-tagged protein is then purified by cation 
exchange chromatography using CM-Sephadex or SP Sepharose Fast flow resins as 
follows: Expressed protein is applied to the resins and only Arg-tagged proteins but not 
bacterial proteins bind to the resins. The resins are washed and Arg-tagged proteins are 
eluted from the resins using high salt (sodium chloride; NaCl) concentration [1, 3, 34].  
Recombinant proteins fused to Arg tag can yield 44% protein with 95% purity [1]. In this 
study, were explored whether an Arg tag could be displayed on MS2 VLPs by inserting 
the tag at the C terminus of MS2 coat protein. An Arg tag displayed on MS2 VLPs will 
enhance the purification of the VLPs. The C-terminus was chosen to insert an Arg tag 
because our lab uses the N-terminus for other insertions (e.g. HPV L2 epitopes). 
2. Materials and Methods 
2.1 Insertion of an Arg tag to C-terminus of MS2 coat protein 
Six Arg residues were inserted on the C-terminus of MS2 coat protein by PCR using a 
reverse primer (MS2-6Arg) that contained 6 Arg residues in-between MS2 coat protein 
sequence and TAA stop codon. Forward primer, primer Sph1, which binds ~293 
nucleotides upstream of the start codon of MS2 coat protein was used in PCR. The reason 
this primer was used is because we already had the primer in the lab and there was no 
need to order a new primer close to the start codon of MS2 coat protein. The sequences of 
reverse primer and forward primer are shown in table 3. 
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Table 3: Sequences of the primers that were used to amplified MS2-6Arg 
Primers Sequences 
Forward 
primer: 
primer   
Sph1 
5’ GATGGTGCATGCAAGGAGATGG 3’ 
Reverse 
primer 
(MS2-
6Arg)R  
5’ AGCAGCCGGATCCTAATTAATTAACCCGGCGTCTATTA 
GCG ACG GCG ACG GCG ACG GTA GAT GCC GGA GTT TGC 
TGC 3’* 
*Stop codon is in red text while Arg tag is shown in yellow background. The underlined 
sequence is the C terminus of MS2 coat protein 
The PCR reaction mixture was set up as described above and the PCR was conducted 
using the following conditions on table 4. 
Table 4: Thermocycling conditions for MS2-Arg-tagged DNA 
Step Temperature Time 
Initial denaturation 94 ºC 2 minutes 
Denaturation 94 ºC 30 seconds 
Annealing 58 ºC 30 seconds 
Extension 68 ºC 1 minute 
Final Extension 70 ºC 5 minutes 
Hold 4 ºC ∞ 
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After PCR, the samples were run on a 1% agarose gel, DNA bands were cut from gel and 
DNA extracted from the gel as described above. A restriction digest was set up as above 
but using Nco1 and BamH1-HF restriction enzymes. Digested DNA were run and 
purified from 1% agarose gel, digested DNA were ligated to plasmid pDSP62 (digested 
with the same restriction enzymes). Ligated reaction (figure 13) was and transformed into 
C41 cells as described above. To check for protein expression, colonies were picked from 
agar plates (kanamycin resistant), grown in LB media and induced with IPTG as 
described above. Control culture was not induced. Colonies that showed protein 
expression were used to prepare plasmid for restriction digest and sequencing to confirm 
cloning of recombinant MS2-6Arg tag. 
2.2 Assessing the solubility of recombinant MS2-Arg-tagged coat 
protein 
Assembly of MS2 coat protein to virus-like particles (VLPs) is a pre-requisite to elicit a 
robust immune response (antibody titers ~104) at low doses (≤ 5 µg) of VLPs.  Ninety 
copies of the MS2 single-chain dimer assemble to form a VLP and the ability of coat 
protein to form VLPs can be predicted following lysis of protein with lysis buffer. If 
protein is likely to form VLPs, it will be in the supernatant (soluble) fraction after lysis 
and centrifugation; otherwise, it will be in the pellet. To assess whether the insertion of 6-
Arg residues on the C-terminus will affect the solubility of the recombinant coat protein 
(potential to fold to VLPs), 3 colonies with high levels of MS2-Arg coat protein 
expression were used to start 2ml overnight cultures (per colony) with LB growth media 
and was subsequently used to separately inoculate 50 ml LB growth media (with 50 ng/ul 
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kanamycin) in duplicate flasks. The cultures were grown shaking for 3 hours at 37 ºC 
after which the cultures were induced with IPTG (at OD600 - 0.6) as described above. One 
group of culture (from duplicate) was grown shaking for an additional 4 hours at the 
same temperature and the other group was induced shaking overnight at room 
temperature. After that, the cultures were divided into two tubes to assess solubility with 
two different lysis and purification buffers. All the tubes were centrifuged at 10,000rmp 
for 20 minutes to pellet the cells. The supernatants were discarded and the pellets saved at 
-20ºC. On the next day, the pellets were dissolved into two different buffers to assess 
which buffer the protein was soluble in. One group of the pellets were resuspended in 
5ml of lysozyme solution with of 0.01g of hen egg lysozyme while the other group was 
resuspended in 5ml of 10mM borax buffer pH 9. The two groups of tubes were incubated 
for 45mintues in ice. Then, 1µl of 10% of deoxycholate was added to each tube to aid 
lysis and kept in ice for 30 minutes. The cells, were the sonicated for 10 minutes (with 
30-second pulses in-between sonication). After sonication, 2 ng/µl of DNase and 2mM 
MgCl2 were added to the lysate and then incubated at 37ºC for one hour. Fifty µl of total 
protein (lysate) was taken from each tube and saved for protein analysis in SDS PAGE 
gel.  The rest of the lysate was centrifuged at 3,700rpm for 30 minutes at 4ºC to separate 
soluble fractions from pellet. The supernatants were transfer to new tubes and labeled 
“supernatant”. SDS PAGE gel was run to confirm the expression and solubility of MS2-
Arg-tagged protein. After confirming the solubility of the protein in borax buffer, the 
soluble protein was tested for purification with 10mM borax at different pH conditions 
(pH 7, 8, and 9) as described below.  
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2.3 Purification of MS2-Arg-tagged protein by an ion cation exchange 
chromatography using CM-Sephadex C-25 and SP Sepharose beads. 
The ability of MS2-Arg-tagged protein to be purified by cation exchange 
chromatography was assessed using two types of beads (SP Sepharose and CM Sephadex  
C-25). The pH of a protein (an ultimately its charge) is very crucial for its purification by 
cation exchange chromatography. In cation exchange chromatography, a positively 
charge protein binds to negatively charged resins in a column. The net charge of the 
protein depends on the pH of the buffer used in lysing the protein. If the pH is less than 
the isoelectric point (pI; pH at which net charge is zero), the net charge on the protein 
will be positive [35]. In our case, the pI of MS2-Arg was 8.73 (calculated using 
http://isoelectric.ovh.org). Thus, to assess the pH at which MS2-Arg could be purified 
using cation exchange chromatography, lysis/solubility of the protein was determined 
using borax buffer at three pH conditions (pH 7, 8 and 9). Lysis and binding of protein to 
SP Sepharose and CM-Sephadex C-25 resins was assessed as follows: 0.07g of SP 
Sepharose resin beads were equilibrated with 400µl of borax buffer (10mM borax at pH 
7, 8 and 9) whereas CM-Sephadex C-25 beads were resuspended in 400µl of borax buffer 
(at pH 7, 8 and 9) and the tubes were inverted for a minute. The tubes were centrifuged at 
1000rpm and supernatant discarded. The whole process was repeated twice.  One ml of 
MS2-Arg-tagged protein (from section 2.2 above) was mixed with beads and the mixture 
was incubated rocking for 3 hours at room temperature. The beads were then spun at 
1000 rpm and the supernatant was collected into a new tube as “unbound”.  Three 
hundred µl of washing buffer (10 mM of borax, at corresponding pH) were used to wash 
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the beads twice (5 minutes per wash). After each wash, the beads were spun down at 
1000 rpm and the supernatant was collected as “washed”. To get pure protein, the beads 
were eluted with 500µlof 400 mM NaCl elution buffer (at pH 7). SDS page gels were run 
using supernatant that were collected before the purification steps, unbound proteins, 
washed proteins from the matrix, and elusion fractions of MS2-arg-tagged protein that 
were collected. 
3. Results 
Following PCR using pDSP62 as a DNA template, a DNA fragment of expected size 
(1,100bp) was amplified (figure 12). 
 
Figure 12. Electrophoretic mobility of amplified MS2-Arg-tagged DNA in an ethidium 
bromide-stained 1% agarose gel. Number 1 is a negative control, numbers 2 and 3 are 
MS2-Arg DNA (1,100 base pair), and number 4 is 1 KB DNA ladder. 
 
The DNA fragment consisted of MS2-Arg coat protein (807bp) plus a (293bp) sequence 
upstream of MS2 coat protein. Restriction digest (BamHI-HF/NcoI) of PCR product 
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release the MS2-Arg fragment (807bp; figure 13), which was then cloned into pDSP62 
plasmid. 
 
Figure 13. Agarose gel of digested amplified DNA using restriction enzymes (NcoI and 
BamHI-HF). Number 1 is 1KB DNA ladder, numbers 2 and 3 are digested MS2-Arg 
DNA. The circled band (MS2-Arg; 807bp) was cut, digested and purified for ligation 
The colonies picked from the agar plate showed protein expression of the expected size 
(~28KD). As shown in figure 14, the cultures from four colonies were highly expressed 
following induction with IPTG while uninduced culture (panel A, lane 1) was not 
expressed. 
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Restriction digest confirmed the size of the cloned DNA fragment. As shown in figure 
15, a 807bp fragment was released from cloned plasmids (pDSP62-Arg). Three of the 
constructs (pDSP62-Arg1, pDSP62-Arg3, pDSP62-Arg4) were sequenced to confirm 
MS2-Arg nucleotide sequence.  
 
Figure 14. Expression of MS2-Arg-tagged coat protein on SDS-PAGE gel. Protein 
expression was induced using IPTG. Circles indicate high expressed protein (~28KD). 
Number 1 in panel A is uninduced colony. Number 2 in panel A, number 3 in panel B and 
number 1 in panel C are protein markers. The remaining numbers in panels A, B, and C 
represent bacteria from individual colonies. Plasmid prep was done from colonies that 
showed expression (circled on the gel; Arg1-Arg4) 
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Figure 15.  Restriction digest of plasmid prep sample ran on a 1% agarose gel (stained 
with Ethidium bromide).  Number 1 is a control pDSP62 plasmid, numbers 2,3,4,5 
represent digestion of plasmid preps from 4 colonies with high expression. Number 6 
is1KB marker 
 
Figure 16 shows that cloned MS2-Arg sequence (query) of pDSP62-Arg1 and pDSP62-
Arg3 have 100% identity with the known sequence (subject sequence). This thus 
confirms the insertion of 6 Arg residues on the C-terminal of MS2. pDSP62-Arg4 also 
show insertion of 6 Arg residues; however, there is an adenosine to a cytosine point 
mutation in the MS2 sequence of this construct (figure 17); which changes Alanine 
amino acid to Aspartate amino acid. Thus, the sequence identity of this construct is 99%. 
pDSP62-Arg2 had lots of mutation in the MS2 sequence and was not pursued further. 
 
 
 
 
  
 38 
BLASTN for MS2-Arg1 and MS2-Arg3 
 
 
 
Figure 16. Sequence alignment of MS2-Arg-tagged DNA (Query sequence) showed 100% 
identity with known (sbjct, which represents subject sequence). Sequence Alignment was 
done using nucleotide BLASTN 
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BLASTN MS2-Arg 4 
 
Figure 17. Sequence alignment of MS2-Arg-tagged DNA (Query sequence) showed 99% 
identity with known (sbjct, which represents subject sequence). The highlighted 
nucleotides in red shows the point mutation. Sequence Alignment was done using 
nucleotide BLASTN 
The solubility (assembly potential) of recombinant MS2-Arg coat protein was assessed 
by lysing bacteria with two different lysis buffers and the supernatant was run on an SDS 
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PAGE gel to check for presence of recombinant protein in the supernatant. Bacterial 
cultures that were induced at 37 ºC were insoluble when lysed with lysozyme or borax 
buffer (data not shown). Similarly, bacteria cultures that were induced overnight at room 
temperature were not soluble in lysozyme lysis buffer (figure 18A). However, when the 
bacteria were lysed using 10% borax buffer (pH 9), two of the constructs representing 
MS2-Arg3 and MS-Arg4 appeared to be soluble (figure 18B). MS2-Arg3 was soluble in 
borax at pH 7 and 9 but not at pH 8 (figure 19). 
 
 
  
Figure 18. Assessing the solubility of MS2-Arg-tagged coat proteins. A) lysis of bacteria 
pellet with lysozyme solution and B) lysis of bacterial pellet with 10mM borax buffer. 
Number 1 is uninduced MS2-Arg 1, number 2 is induced MS2-Arg 1, number 3 is induced 
MS2-Arg 3 and number 4 is induced MS2-Arg 4 
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whereas MS2-Arg4 seemed to be soluble at pH 9 and to a less extend pH 7 (figure 20).  
Thus, borax at pH 7 was explored with SP Sepharose and CM-Sephadex C-25 beads to 
purify MS2-Arg3. MS2-Arg4 was not explored for purification because it was soluble at  
pH 9, which is above the pI. 
Figure 19. Assessing the solubility of MS2-Arg3-tagged coat proteins at different pH 
conditions. Number 1 is Marker. Number 2 is uninduced Arg3, number 3 is induced Arg3 
lysate (lysed with urea), number 4 is Arg3 lysate and supernatant lysed with 10mM borax 
at pH7,  number 5 is Arg3 lysate and supernatant lysed with 10mM borax at pH 8, 
number 6 is Arg3 lysate and supernatant lysed with 10mM borax at pH 9, and positive 
control MS2 
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Figure 20. Assessing the solubility of MS2-Arg4-tagged coat proteins at different pH 
conditions. Number 1 is Marker, number 2 is uninduced Arg3, number 3 is induced Arg3 
lysed with urea (positive control), number 4 is Arg 4 lysate and supernatant lysed with 
10mM borax at pH 7,  number 5 is Arg4 lysate and supernatant lysed with 10mM borax 
at pH 8, number 6 is Arg4 lysate and supernatant lysed with 10mM borax at pH 9, and 
positive control MS2 
 
While small amount of MS2-Arg3 could be purified using CM-Saphadex C-25 resins, the 
protein could not be purified using SP Sepharose. As shown in figure 21, a small fraction 
of MS2-Arg3 was eluted from CM-Sephadex C-25 resins following elution with 0.4M 
NaCl. 
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Figure 21. Purification of recombinant protein MS2-Arg3 protein. The recombinant 
protein was purified by cation exchange chromatograph using CM-Saphadex C-25 
beads. Number 1 is uninduced Arg3, number 2 is induced Arg3 lysed with urea (positive 
control), number 3 total protein before purification, number 4 unbound protein (flow 
through) after adding total protein to column, numbers 5-6 is flow through of column 
washes, numbers 7 and 8 are fractions after elution, number 9 CM-Saphadex C-25 beads 
after elution, and number 10 is a marker. 
 
Purification using SP Sepharose resins was unsuccessful. Most of the protein did not bind 
to the SP Sepharose beads (figure 22); MS2-Arg3 protein was present in the unbound 
fraction. Additionally, the small fraction of MS2-Arg3 that was bound to the beads was 
washed during the wash step (figure 22). 
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Figure 22. Purification of recombinant protein MS2-Arg3 protein by cation exchange 
chromatograph using SP-Sepharose FF beads. Number 1 is Arg3 lysate (lysed with urea; 
positive control), number 2 is total protein before purification, number 3 is unbound 
protein (flow through) after adding total protein to column, numbers 4-5 is flow through 
of column washes,, number 6 is fraction after elution, and number 7 is a marker 
  
4. Conclusions 
To develop a platform that could enhance the purification of recombinant MS2 VLPs, we 
inserted, successfully, 6-Arg residues on the C-terminus of MS2 bacteriophage coat 
protein. Solubility studies (ability to form VLPs) showed the MS2-Arg is soluble in 
10mM borax and can be purified in small quantity, using CM-Sephadex C25 resins (at 
pH 7), from contaminating bacterial proteins. Future studies are needed to assess (using 
transmission electron microscopy) whether the purified MS2-Arg can assemble into 
VLPs. Recombinant bacteriophage VLPs displaying an Arg tag will enhance VLPs 
purification following gel filtration purification and will be a valuable tool for vaccine 
development. 
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